1. Academic Validation
  2. FNDC5/Irisin inhibits pathological cardiac hypertrophy

FNDC5/Irisin inhibits pathological cardiac hypertrophy

  • Clin Sci (Lond). 2019 Mar 1;133(5):611-627. doi: 10.1042/CS20190016.
Qing Yu 1 Wenxin Kou 1 Xu Xu 1 Shunping Zhou 1 Peipei Luan 1 Xiaopeng Xu 1 Hailing Li 1 Jianhui Zhuang 1 Jun Wang 2 Yifan Zhao 3 Yawei Xu 3 Wenhui Peng 3
Affiliations

Affiliations

  • 1 Department of Cardiology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • 2 Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, U.S.A.
  • 3 Department of Cardiology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China [email protected] [email protected] [email protected].
Abstract

Cardiac hypertrophy is a common pathophysiological process in various cardiovascular diseases, which still has no effective therapies. Irisin is a novel myokine mainly secreted by skeletal muscle and is believed to be involved in the regulation of energy metabolism. In the present study, we found that irisin expression was elevated in hypertrophic murine hearts and serum. Moreover, angiotension II-induced cardiomyocyte hypertrophy was attenuated after irisin administration and aggravated after irisin knockdown in vitro Next, we generated transverse aortic constriction (TAC)-induced cardiac hypertrophy murine model and found that cardiac hypertrophy and fibrosis were significantly attenuated with improved cardiac function assessed by echocardiography after irisin treatment. Mechanistically, we demonstrated that FNDC5 was cleaved into irisin, at least partially, in a disintegrin and metalloproteinase (ADAM) family-dependent manner. ADAM10 was the candidate Enzyme responsible for the cleavage. Further, we found irisin treatment activated AMPK and subsequently inhibited activation of mTOR. AMPK inhibition ablated the protective role of irisin administration. In conclusion, we find irisin is secreted in an ADAM family-dependent manner, and irisin treatment improves cardiac function and attenuates pressure overload-induced cardiac hypertrophy and fibrosis mainly through regulating AMPK-mTOR signaling.

Keywords

AMPK; FNDC5; cardiac hypertrophy; irisin.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100211
    99.46%, MMP/TACE/ADAM Inhibitor